Pdb54 - Estimated Events Avoided and Cost Offsets Associated With Using Canagliflozin to Treat Patients With Type Two Diabetes Mellitus (T2dm) With or at High Risk of Developing Cardiovascular Disease (Cvd) in England

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.759
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The CANVAS Program: Implications of Canagliflozin on Reducing Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2019English

Pdb73 - Indirect Cost-Effectiveness Analysis of Empagliflozin Compared to Canagliflozin for Patients With T2dm and Cardiovascular Disease in the Spanish National Health Service

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Canagliflozin Improves Risk Factors of Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus and Metabolic Syndrome

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2017English

Improving Blood Pressure Control in Patients With Diabetes Mellitus and High Cardiovascular Risk

International Journal of Hypertension
Internal Medicine
2010English

Canagliflozin Should Be Prescribed With Caution to Individuals With Type 2 Diabetes and High Risk of Amputation

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Advances in Therapy
MedicinePharmacology
2015English

Effect of Canagliflozin on Serum Uric Acid in Patients With Type 2 Diabetes Mellitus

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Target Values of Cardiovascular Risk Factors Are Not Associated With All-Cause Mortality in Patients With Type 2 Diabetes Mellitus

PLoS ONE
Multidisciplinary
2015English

Risk of Major Cardiovascular Events in Patients With Type 2 Diabetes With and Without Prior Cardiovascular Events: Results From the Leader Trial

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy